Matthew Winton
2023
In 2023, Matthew Winton earned a total compensation of $1.5M as Senior Vice President and Chief Operating Officer at Inozyme Pharma.
Compensation breakdown
| Bonus | $50,000 |
|---|---|
| Non-Equity Incentive Plan | $150,000 |
| Option Awards | $1,022,196 |
| Salary | $326,250 |
| Other | $181 |
| Total | $1,548,627 |
Winton received $1M in option awards, accounting for 66% of the total pay in 2023.
Winton also received $50K in bonus, $150K in non-equity incentive plan, $326.3K in salary and $181 in other compensation.
Rankings
In 2023, Matthew Winton's compensation ranked 756th out of 2,918 executives tracked by ExecPay. In other words, Winton earned more than 74.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 756 out of 2,918 | 74th |
Division Manufacturing | 439 out of 1,608 | 73rd |
Major group Chemicals And Allied Products | 300 out of 901 | 67th |
Industry group Drugs | 294 out of 864 | 66th |
Industry Pharmaceutical Preparations | 195 out of 622 | 69th |
Source: SEC filing on April 26, 2024.
Winton's colleagues
We found three more compensation records of executives who worked with Matthew Winton at Inozyme Pharma in 2023.